Aura Biosciences, Inc. (AURA) Fundamental Analysis: Bull vs. Bear Case

AURA

Aura Biosciences, Inc.

Fundamental data last updated:October 28, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

11/05/2026

Business Summary

Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.

VALUATION

P/E

-3.49

Market Cap ($M USD)

$644.53M

Forward P/E

-10.57

PEG

0.23 PRICE TO SALES

0.00 PRICE TO BOOK

1.87 EV / EBITDA

-4.48

5-Year Average P/E

Free Cash Flow Yield

-15.93%

DCF Value

$0.67

Graham Number

N/A

Price to FCF

-6.28

EV to FCF

-5.78

Earnings Yield

-22.22%

FCF Yield

-15.93%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$1.38

Next Year EPS Growth Estimate

-$1.67

Next Year Revenue Growth Estimate

$19.20M

Return on Equity (ROE)

-73.18%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.05 Piotroski F-Score

2 Altman Z-Score

9.48 Return on Invested Capital (ROIC)

-41.61%

Current Ratio

16.82 Quick Ratio

16.82 Net Debt to EBITDA

0.39 Interest Coverage

0.00 Gross Profit margin

0.00%

FCF PER SHARE

$-1.08

REVENUE PER SHARE

$0.00

Gainseekers Quantitative Analysis

Summary

AURA’s valuation paints a perplexing picture. Despite a negative DCF Value, the market has priced the stock significantly above this metric, suggesting a disconnect or speculative optimism. The Forward P/E and Earnings Yield are deep in negative territory, indicating potential earnings struggles. However, the Altman Z-score of 4.78 suggests financial stability, hinting at a paradox where the company is both risky and resilient. This duality makes it a complex play for investors seeking clarity.

AI Exposure / Tech Reliance

Operating in the biotechnology sector, AURA is well-positioned to leverage AI advancements for drug discovery and personalized medicine. The industry's inherent need for innovation aligns with tech-driven efficiencies, potentially enhancing R&D productivity. This adaptability could be a catalyst for future growth in a rapidly evolving landscape.

The Bull Case

For the optimistic investor, AURA offers a compelling narrative. The company's low Debt/Equity ratio of 0.13 and robust Current Ratio of 8.15 highlight financial prudence and liquidity. Despite a negative ROIC, the high Altman Z-score underscores a solid balance sheet. These factors, combined with a consensus "Buy" rating, suggest institutional confidence and potential for long-term value creation.

The Bear Case

Yet, the bear case cannot be ignored. AURA's Price/Book ratio of 3.70 and negative Price to FCF indicate overvaluation and cash flow challenges. The Piotroski F-Score of 1 signals weak financial health, raising red flags about operational efficiency. With the stock trading near its 52-week high, technical overextension adds to the risk profile, making it a precarious bet.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$17.50

Institutional Ownership %

1-Year Beta

0.41 Insider Buying % (6 Mo)

Distance to 52-Week High

53.50%

Distance to 52-Week Low

23.89%

EARNINGS SURPRISE %

-28.00%

50-DAY SMA

$6.84

200-DAY SMA

$6.69

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.